L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels
Phase II Study of L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Level
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
A PHASE2 clinical study on Asthma and Inflammation, this trial is completed. The trial is conducted by National Heart, Lung, and Blood Institute (NHLBI) and has accumulated 13 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2019 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- Nicholas Kenyon
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Sacramento, United States